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The prevalence of alcohol abuse is >26% in the US population. The 
socioeconomic burden associated with alcohol is $249 billion/year, where 75% of this 
cost is related to binge drinking. Binge drinking is a problematic pattern of behavior that 
often leads to alcohol use disorders (AUD). Binge drinking is defined by the NIAAA as 
having 4-5 drinks within 2 hrs and/or achieving a blood alcohol level (BAL) >80 mg%. 
Limited access ethanol drinking paradigms are used to model binge/intoxication in 
animal models (however, not all limited access paradigms and animal strains drink to 
intoxication). In the limited access Drinking in the Dark (DID) paradigm, mice are offered 
an ethanol solution early into the active period of their circadian cycle and can achieve 
BALs >80mg%, suggesting they drink to intoxication (1). C57BL/6J mice are typically 
reported as high drinking and can achieve BALs >80mg% in the DID paradigm, however 
significant inbred strain differences have been observed suggesting there exists a 
genetic contribution to this phenotype (2, 3). The DID assay was used to independently 
create two lines of mice, HDID-1 and HDID-2, that were selectively bred (from HS/Npt 
progenitors) for high BALs after DID (4, 5). HDID and HS/Npt mice have been 
extensively characterized; HDID mice represent a unique genetic animal model of risk 
for drinking to intoxication (6–15). Current FDA approved compounds for AUD 
treatment, as well as several investigational compounds, have been tested for efficacy 
in reducing binge-like drinking using the DID paradigm in C57BL/6J and HDID mice, as 
well as other genotypes (16–21). Together, this work suggests that testing potential 
therapies in more than strain may represent a more beneficial strategy for clinically 
translational studies. 
Alcohol abuse leads to long lasting changes in reward- and stress-related 
neuronal circuitry. A significant point of convergence for this circuitry is the nucleus 
accumbens (NAc). Koob and Volkow (2010) reviewed decades of clinical and pre-
clinical studies to address the neural circuitry associated with the three stages of the 
addiction cycle: binge/intoxication, withdrawal/negative affect, and 
preoccupation/anticipation (22). The NAc is identified as an important region for each of 
these three stages, further supporting its role as a significant point of convergence in 
the neurocircuitry of addiction. Lesions of the NAc core reduce limited access alcohol 
intake in mice and relapse rates in alcohol dependent patients but may cause 
irreversible cognitive deficits in humans (23–25). Cassataro et al. (2014) reported that 
inhibiting the NAc core [via clozapine-n-oxide or CNO, and hM4Di, an inhibitory 
Designer Receptor Exclusively Activated by Designer Drugs (DREADD)], reduced 
limited access drinking in male C57BL/6J mice (23). There is also extensive evidence 
that stimulating, or increasing activity in these brain regions reduces alcohol drinking, 
craving, and relapse (26). To achieve this, clinical studies have applied deep brain 
stimulation (DBS) to the NAc in humans (27–29). Human studies were carried out in 
treatment resistant alcoholics, where NAc DBS of the shell relieved symptoms of 
craving and reduced relapse (27). Knapp et al. (2009) showed that DBS of either the 
NAc core or shell reduces alcohol drinking in rats (using a continuous access paradigm) 
(30). Henderson et al. (2010) tested the efficacy of NAc DBS (in rats selectively bred for 
high alcohol preference; P rats) to reduce alcohol intake in two paradigms (31). In the 
first experiment, they found that NAc DBS acutely reduced alcohol drinking in rats with 
chronic drinking experience (continuous access) and in a second experiment they found 
that NAc DBS reduced relapse-like drinking (drinking after chronic continuous access 
followed by a period of forced abstinence). NAc DBS has also been shown to effectively 
reduce craving for morphine, heroin, and cocaine (32–34). Many of these studies report 
that DBS of either the NAc core or shell (or both) are effective in reducing drug-related 
behaviors in males. Although DBS of the NAc decreases alcohol drinking and craving, 
its effects are not lasting (reviewed in (35)).  
The promising results of NAc DBS studies led us to test whether DREADDs 
could be used to alter neuronal activity in the NAc and whether they could alter binge-
like drinking. There are two sub-regions of the NAc, the shell (more medial and ventral 
aspect) and core (more lateral and dorsal aspect). In Purohit et al. (2018), we found that 
increasing activity (via CNO/hM3Dq) in the entire NAc, or just the NAc core is sufficient 
to decrease binge drinking in C57BL/6J females. Here, we test whether this effect is 
observed in another high drinking mouse line (HDID-1). DREADDs are mutagenized 
GPCRs, and since we know GPCRs play an important role in neuroplasticity, we test 
the hypothesis that chronic stimulation of DREADDs could lead to lasting reductions in 
binge-like drinking. We hypothesize that this behavioral plasticity can be observed at the 
molecular level via lasting changes in the transcriptome and in neuronal morphology. 
Here, we focused on identifying genes and biological pathways that are altered with 
chronic binge-drinking and ameliorated with chronic CNO treatment. We then 
pharmacologically targeted these biological pathways to determine whether they reduce 
binge like drinking.  
 
 
METHODS AND MATERIALS 
Experimental Animals: Adult High Drinking in the Dark line 1 (HDID-1) (generously 
provided by Dr. John Crabbe, Portland, Oregon, USA) mice aged 2-5 months were used 
for experiments in this study. HDID-1 mice are a genetic model of risk for drinking to 
intoxication and were selectively bred from a genetically heterogeneous stock, HS/Npt 
(4, 5). Mice were bred and maintained in a reversed 12/12-h light/dark cycle, with lights 
off at 08:30 and lights on at 20:30. Cages were made of polycarbonate (28 x 17 x 11.5 
cm) containing about 2.5 cm of cob bedding. Purina brand food (5LOD, PMI Nutrition 
International, Brentwood, MO) was suspended in a wire-top, and food and water were 
available ad libitum. All procedures in this study were performed in accordance with NIH 
Guidelines for the Care and Use of Laboratory Animals and were approved by the VA 
Portland Health Care System’s Institutional Animal Care and Use Committee. 
 
Drinking in the Dark (DID): Binge-like drinking of ethanol in mice was assessed using 
Drinking in the Dark (36). All mice had daily access to 20% ethanol (v/v, in tap water; 
Decon Laboratories, Inc., PA, USA) for two hours (offered three hours into lights off).  
 
Drugs: For experiments 1 and 2: 30 minutes prior to DID, mice received IP injections of 
either vehicle [VEH; 1% DMSO (Hybri-Max, Sigma Life Sciences) in saline (0.9% NaCl; 
Baxter International, Illinois)], or 1 mg/kg CNO (1% DMSO in saline; RTI International, 
North Carolina, USA). For experiment 3, 60 minutes prior to DID, mice were injected IP 
with either vehicle (5% DMSO in Dulbecco’s phosphate buffered saline; Gibco, Sigma 
Life Sciences, MO, USA) or 5 or 20 mg/kg LMK 235 (Selleck Chemicals, LLC, TX, 
USA). 
 
Experiment 1: Female HDID-1 mice (S32.G34) were anesthetized with a mixture of 
ketamine (125mg/kg) and xylazine (12.5mg/kg) in saline and received bilateral 
stereotaxic infusions of 1uL purified high titer AAV into the NAc [rAAV2-hSyn-eGFP 
(GFP; n=15), rAAV2-hSyn-HA-hM3D(Gq)-IRES-mCitrine (hM3Dq; n=13), or rAAV2-
hSyn-HA-hM4D(Gi)-IRES-mCitrine (hM4Di; n=8); (from bregma, in mm: angle 10°, AP 
+1.5, Lat +1.7, DV -4.6 and -4.0; 0.5 uL delivered at DV -4.6 and 0.5 uL delivered at DV-
4.0)]. AAV titers were 2-3.5x10^12 vg and were purchased from the University of North 
Carolina Viral Vector Core. Mice were individually housed and habituated to novel 
sipper tubes one week prior to DID. The DID experiment was 6 weeks long. Mice were 
serially treated with vehicle prior to DID during week 1 to establish baseline drinking, 
then CNO during weeks 2-5 to measure the effects of chronic treatment, and then mice 
were treated with vehicle again during week 6 to determine if there were any lasting 
effects of chronic CNO treatment. The serial treatment is represented in the figures as 
VEH/CNO/VEH. Ethanol intake was measured as described in Purohit et al. (2018) (36). 
At the completion of this study, mice were deeply anesthetized and transcardially 
perfused with 0.01 M PBS and 4% w/v paraformaldehyde (PFA). Brains were extracted, 
sectioned at 30 µm using a freezing stage microtome (Model No. 860, American Optical 
Corp., Buffalo, New York, USA), and processed for immunofluorescence to verify 
injection placements.  
 Immunohistochemical staining was performed following standard procedures 
using rabbit anti-GFP or anti-HA primary antibody (anti-GFP: AbCam, Catalog#ab290, 
1:20,000 diultion; anti-HA: Cell Signaling Technologies, Catalog #3724S, 1:1000 
dilution) and goat anti-rabbit Alexa 488 secondary antibody (Thermofisher Scientific, 
Catalog #A11088, 1:500 dilution factor). Brain sections were mounted on microscope 
slides (Fisherbrand, #12-550-15) using Vectashield Antifade Mounting Medium with 
DAPI (Vector Laboratories, Burlingame, CA) and observed using an Olympus BX60 
fluorescence microscope (Olympus, Center Valley, PA, USA). Animals were excluded if 
expression was not localized to the NAc (hM4Di n=2, GFP n=3). 
 
Experiment 2: Female HDID-1 mice (S35.G37) were stereotaxically injected with 0.5ul 
uL rAAV2/5-CMV-Cre-GFP and 0.5uL rAAV2-hSyn-DIO-hM3Dq-mCherry bilaterally into 
the NAc (from bregma, in mm: angle 10°, AP +1.34, Lat +1.5, DV -4.5). AAV titers were 
4-8x10^12 vg and were purchased from the University of North Carolina Viral Vector 
Core (Cre) and Add Gene (DIO constructs). Mice were individually housed and 
habituated to novel sipper tubes one week prior to DID. The DID experiment was 6 
weeks long (as described for experiment 1); however, there were 2 fluid groups (water 
or ethanol) and 2 treatment groups (VEH/VEH/VEH or VEH/CNO/VEH). Mice were 
serially treated with vehicle prior to DID during week 1 to establish baseline drinking, 
then vehicle or CNO during weeks 2-5 to measure the effects of chronic treatment, and 
then mice were treated with vehicle again during week 6 to determine whether there 
were any lasting effects of chronic CNO treatment. Ethanol intake was measured as 
described in Purohit et al. (2018). For transcriptomic analysis, mice (n=11-12/fluid 
type/treatment) were euthanized one day after the last DID session via cervical 
dislocation and rapid decapitation. Frozen tissue punches were collected from the NAc 
and processed for RNA Sequencing. For neuronal morphology analysis, female HDID-1 
mice (S34.G36; n=4-5/fluid type/treatment) were deeply anesthetized and transcardially 
perfused with 0.01 M PBS and 4% w/v paraformaldehyde (PFA). Brains were extracted 
and placed in 4% PFA for 24 hours at 4ºC before processing for Golgi-Cox staining (as 
described in (37)). After 14 days at room temperature and low ambient light, the tissue 
was transferred into a 30% w/v sucrose solution for 24-72 hours (low light at 4ºC), prior 
to sectioning and mounting. Brains were sectioned coronally using a Compresstome at 
200 μm (Model VF 300-0Z Microtome with AutoZero Z technique, Precisionary, 
Greenville, NC, USA) and mounted on gelatin-coated slides. Slides were prepared 
according to section 2.3 of Bayram-Weston et al., 2016, and cover-slipped with 
Permount™ Mounting Medium (Fisher Scientific Co., Waltham, MA, USA). 
 
Experiment 3: Adult male and female HDID-1 mice (S38.G40, S39.G41, S41.G43) 
were individually housed and habituated to novel sipper tubes one week prior to DID. 
Mice were tested 4 days per week (as in (1)). Mice were serially treated with vehicle 
prior to DID (during weeks 1 or 1&2) to establish baseline drinking, and then 0, 5, or 
20mg/kg LMK 235 over the next 2 weeks to measure the effects of chronic treatment 
with this HDAC4/5 inhibitor. Ethanol intake was measured using volumetric tubes in 2 hr 
intervals on all 4 days (8). 
 
Microscopy: NAc medium spiny neurons were traced with the software Neurolucida 
(Version 11, MBF Bioscience, Williston, VT, USA) on a Leica DM500b microscope using 
a DFC36 FX camera. Data analyzed were complexity (sum of the terminal orders + the 
number of terminals)*(total dendritic length/number of dendrites), average dendrite 
length (µm), node and end quantity, total dendritic length (µm), sum of the terminal 
orders (number of sister branches encountered when tracing a dendrite from the tip 
back to the cell body), dendrite quantity, branch sum (total number of segments 
between node), sholl analysis intersections, sholl analysis length (µm), sholl analysis 
nodes, sholl analysis ends, and sholl analysis area under the curve. The sholl analysis 
radii were 10 µm. 
 
RNA Sequencing and Validation of viral gene transduction: NAc tissue punches 
were mechanically homogenized in PureZol and the RNA isolated using the Aurum 
Total RNA Fatty and Fibrous Tissue kit (Bio-Rad Laboratories, Inc., Hercules, CA). RNA 
(100 ng) was processed to cDNA using the BioRad iScript cDNA synthesis kit (Catalog 
#: 1708890; Bio-Rad Laboratories, Inc., Hercules, CA) according to manufacturer’s 
protocol. Quantitative real-time PCR was used to measure expression of mCherry to 
confirm viral expression of hM3Dq-mCherry in samples. A custom mCherry (FOR: 5’-
AGCGCGTGATGAACTTCGA -3’ REV: 5’ CGCAGCTTCACCTTGTAGATGA-3’; 5’ 6-
FAM, 3’ Iowa Black FQ) primer set and Rps18 (Mouse, FAM, qMmuCEP0053856) 
probe were used and purchased from Bio-Rad Laboratories, Inc., Hercules, CA. 
mCherry expression levels (relative to 18s) were verified as detectable and similar for all 
samples (data not shown). RNA samples were then sent to the Massively Parallel 
Sequencing Shared Resource (MPSSR) at OHSU for quality assessment (via 2100 
BioAnalyzer, Agilent Technologies, Palo Alto, CA). The library was prepared using the 
Illumina TruSeq RNA-Seq Library Protocol and quality checks were performed using a. 
Sequencing was executed via an Illumina HiSeq 2500 Sequencer (Illumina, San Diego, 
CA, USA) with poly(A)+ stranded selection and paired-end reads at 50 cycles.  
 
Data analysis and statistics:  
Behavior: For experiments 1 and 2, daily alcohol intake data was averaged for each 
mouse for each treatment period. Intake data were then analyzed using a repeated 
measure one-way analysis of variance (ANOVA) was performed to determine effect of 
treatment period on drinking. For significant results (p<0.05), Post-hoc tests were 
carried out to compare baseline drinking to CNO treatment and washout periods. For 
experiment 3, drinking data for each 2 hr interval was averaged for each period 
(baseline vs treatment weeks). Data was analyzed using a two way repeated measures 
ANOVA (dose x treatment period). 
 
Transcriptomic Analysis: Raw FASTA files generated from sequencing were aligned to 
the Genome Reference Consortium Mouse Reference 38, based on the Mus musculus 
strain C57BL/6J (GRCm38; also known as mm10). File quality was assessed using 
FastQC (38) and alignment was run using STAR: ultrafast universal RNA-seq aligner 
(39) (version: 2.6.0) where paired-end reads were specified, the maximum number of 
mismatches per pair was indicated as 3 and maximum number of multiple alignments 
allowed per read was indicated as 1. Count data was generated using HTSeq (version 
0.9.1) (40) against the Encode vM4 annotation with paired-end read order specification.  
After filtering, normalization and differential expression were performed using 
Bioconductor (version 3.34.9) in R (41). The Limma voom (42) function was utilized to 
perform empirical Bayes-moderated t-statistics to identify Differentially Expressed 
Genes (DEGs, p < 0.05) between fluid and treatment groups. Mean-variance 
relationships and observational-level weights were calculated from log2-counts per 
million (log-CPM). Gene expression overlap was identified using BioVenn (43). 
Weighted gene co-expression network analysis (WGCNA; version 1.67) was performed 
using R implementation (44). A signed, hybrid co-expression network was constructed. 
24,421 genes met the cut off of 1 CPM. Prior to network construction, 10% of genes 
exhibiting the lowest correlation values were removed via SUMCOR as in Tritchler et 
al., 2009 (45). The co-expression network was constructed via Pearson correlation 
between all gene pairs and the exponentiation of the resulting absolute value to a power 
beta = 7. A consensus network was constructed utilizing samples from all sequenced 
RNA samples. Modules were detected in each network via hierarchical clustering where 
average linkage and the WGCNA cuttreeHybrid function was used with the following 
parameters: cutHeight = 0.998, minClusterSize = 100, and deepSplit = 0. The resulting 
modules were identified by arbitrarily chosen colors. Total network connectivity (degree) 
of each gene was calculated via the sum total of all edges in the network, where 
modular connectivity restricted the edges included to the gene’s own module. Pseudo 
and Riken genes exhibiting abnormally high connectivity were sequestered and 
removed. Module quality was assessed using the WGCNA modulePreservation 
function. The enrichR algorithm (46, 47) was used to identify gene ontology annotation 
enrichment for biological pathways.  
 
Morphology: As the data was nested, with multiple neurons within a brain (dependent) 
being compared to multiple neurons from other brains (independent) we used a linear 
mixed effect analysis (48). We did this using R and the package lme4 (49) to perform a 
multilevel analysis. The animal was accounted for as a random effect, due to multiple 
cells for each animal being examined. We used the fluid type (EtOH vs. H2O) and the 
treatment (CNO vs. Vehicle) as fixed effects, and p-values were obtained by likelihood 
ratio tests. For all morphometric parameters, we examined the main effect of both 
variables, as well as their interaction. We then corrected for multiple comparisons using 
the Benjamini-Hochberg approach (50) to adjust the p-values to the q-values of the 
False Discovery Rate (FDR). Sholl analyses were analyzed by radius as well as area 
under the curve (AUC). P-values and q-values less than 0.05 were considered 





Experiment 1: Chronically increasing Gq signaling in the NAc produces lasting 
reductions in binge-like drinking  
To identify the effect of manipulating NAc activity (via CNO and hM3Dq- or hM4Di-
DREADDs) on binge-like drinking, HDID-1 mice were subjected to a limited access 
Drinking in the Dark (DID) paradigm. The effects of treatment (via serial administration 
of vehicle, CNO, and vehicle) on ethanol binge-like drinking in mice expressing GFP 








GFP or hM4Di 
in the NAc did 
not exhibit significant changes in ethanol intake during CNO treatment or vehicle 
washout periods (relative to baseline intake). However, mice expressing hM3Dq in the 
NAc exhibited a significant reduction in ethanol intake during chronic CNO treatment 
and during the vehicle washout periods relative to vehicle baseline intake [one way 
ANOVA - F(2,35)=4.84, p < 0.01; post-hoc - VEH(baseline) vs CNO, p < 0.05; 
VEH(baseline) vs VEH(washout), p <0.05]. This suggested that chronically increasing 
Gq signaling in the NAc produced lasting effects on binge-like drinking behaviors. 
 
Figure 1. Chronically increasing Gq signaling in the NAc produced lasting reductions 
in binge-like drinking. Mean (+/- SEM) 2‐hour ethanol (EtOH) intake during drinking in the 
dark (DID) is shown as a function of treatment period for each group as follows: (A) GFP, 
(B) hM4Di, and (C) hM3Dq. (C) Significant decreases were observed only in hM3Dq during 
CNO treatment and washout, relative to baseline intake [one way ANOVA - F(2,35)=4.84, p 
< 0.05; post-hoc - VEH(baseline) vs CNO, * p < 0.05; VEH(baseline) vs VEH(washout), * p 
<0.05]. No significant differences in intake over treatment periods were observed for GFP 
and hM4Di groups. 
Experiment 2: Chronically increasing Gq signaling in the NAc produces lasting 
reductions in binge-like drinking, the transcriptome, and neruonal morphology. 
Results from experiment 1 suggested that chronic stimulation using hM3Dq 
excitatory DREADDs produced a robust and lasting reduction in binge-like drinking in 
our animal model, thus the 
previous study was 
replicated using hM3Dq 
DREADDs exclusively. Here, 
the results of chronic CNO 
administration in mice 
hM3Dq excitatory DREADDs 
in the NAc were similar to 
data from experiment 1. 
Figure 2A shows ethanol 
drinking in response to 
chronic treatment with vehicle throughout the duration of the experiment (open bar). 
This group experienced no significant changes at any point of the experiment in 
average ethanol intake(g/kg/2hr DID session) relative to baseline intake.  
Figure 2. Chronically increasing Gq signaling in the NAc produces 
lasting reductions in binge-like drinking. Mean (+/- SEM) 2‐hour intake 
during DID weeks is shown as a function of treatment period. (A) No 
significant decreases in binge-like EtOH intake were observed in response 
to chronic treatment with vehicle throughout the duration of the experiment. 
(B) Robust, significant reductions in binge-like EtOH intake were observed in 
response to CNO treatment and these reductions persisted during the 
washout period [one way ANOVA - F(2,35)=10.49, p < 0.01; post-hoc test 
revealed significant differences for VEH baseline vs CNO (** p < 0.01) and 
VEH baseline vs VEH washout (* p < 0.05)].  
Conversely, the group treated with CNO shown in Figure 2B experienced significant and 
lasting reductions in ethanol intake during CNO treatment [one way ANOVA - 
F(2,35)=10.49, p < 0.01; Dunnett post-hoc test revealed significant differences for VEH 
baseline vs CNO (p < 0.01) and VEH baseline vs VEH washout (p < 0.05)]. Replication 
of this finding provides strong evidence for behavioral plasticty. We next sought to  
 
identify how this plasticity manifested on a transcriptomic and morphological level. 
Figure 3. Gene expression changes 
produced by chronic binge drinking and 
stimulation of Gq signaling in the NAc. (A) 
The venn diagram represents overlapping or 
unique DEGs (p<0.05) in each group based 
on pairwise compairson of all groups to 
H2O(VEH) mice. (B) Gene expression 
patterns of DEGs associated with binge-like 
EtOH drinking identified in (A) across groups 
are visualized by heatmaps, where blue 
corresponds to positive expression, red 
negative and gray minimal to no change in 
expression. The left panel of (B) represent 
688 DEGs associated with EtOH(VEH), the 
middle panel represents the 1431 associated 
with EtOH(CNO) and the right panel 
represents the 612 associated with 
H2O(CNO). (C) To identify genes changed 
with chronic binge drinking that were 
ameliorated with CNO, we highlight the 
expression patterns in this heatmap for the 
top 47 DEGs with greatest variability 
(pairwise Euclidean distance > 1.5 standard 
deviations from mean) for the 688 unique to 
EtOH (VEH) as compared with other 
treatment/fluid groups. (D) A clustergram is 
shown to visualize results from GO 
performed on the 688 DEGs identified from 
EtOH (VEH) shown in (A). Here enriched 
terms are shown in each row and input 
genes are in columns. The cell colors in the 
matrix indicate if a gene is associated with a 
term (red) based on its combined z-score 
and p-value. The rank of enriched terms is 
determined by the combind p-value and z-
score of each term where the light red 
indicates high rank and significance and dark 
red indicates low. (E) Normalized gene 
expression levels of Hdac4 are shown for 
each treatment and fluid group. A significant 
increase in normalized expression was 
observed between fluid types receiving 
vehicle treatment [two-way ANOVA: Fluid x 
Treatment interaction - F(1,41)=4.45, p< 
0.05; main effect of fluid - F(1,41)=6.23, 
p<0.05; post-hoc test revealed EtOH(VEH) 
vs H2O(VEH), p < 0.05)].  
 
To identify gene expression changes that change with binge drinking and CNO 
treatment, differential expression analysis was performed using four groups from 
experiment 2. These four groups were defined as untreated binge-drinking 
(EtOH(VEH)), treated binge-drinking EtOH(CNO), treated water drinking (H2O(CNO)) 
and control water drinking (H2O(VEH)) animals. Comparisons made between groups 
involved the pairwise compairson of all groups with the control H2O(VEH) only. In this 
way, we identified differentially expressed genes from all groups relative to the control. 
The lists of differentially expressed genes were then compared for either overlapping or 
unique genes based on each group.  
We identified that there were 1,473 differentially expressed genes (p < 0.05) in 
EtOH(VEH) relative to control. In EtOH(CNO) relative to the control, 2,377 differentially 
expressed genes were observed. We observed 1,157 differentially expressed genes 
H2O(CNO) as compared with controls. The overlap in these DEGs is illustrated in 
Figure 3A. Here, 688 DEGs were uniquely differentially expressed in EtOH(VEH). In 
EtOH(CNO) 1,431 genes were uniquely differentially expressed and in H2O(CNO) 612 
genes were differentially expressed. The overlap for DE was highest between the EtOH 
(VEH) and EtOH (CNO) (N =513) and lowest between EtOH (VEH) and H2O (CNO) 
(N=112). Expression patterns for the unique DE genes identified for EtOH (VEH), EtOH 
(CNO) and H2O (CNO) are shown in Figure 3B. Each column represents a group, while 
each row represents a gene transcript. Transcripts are color coded based on log-2fold 
change from positive (blue) to negative (red). Gray indicates minimal change in 
expression. 
To identify DE genes effected by ethanol that were rescued by CNO, a Euclidean 
distance measure clustering was used. The top 47 genes with greatest variability 
(pairwise Euclidean distance > 1.5 standard deviations from mean) in expression 
patterns unique to EtOH (VEH) are illustrated in Figure 3C. Genes in this list tended to 
be overrepresented in GO categories including thiamine-containing compound 
metabolic processes, myeloid dendritic cell activation and ammonium transmembrane 
transport. This indicates that gene expression changes significantly perturbed by binge-
drinking effect many a variety of biological pathways in a complex manner.  
The results of gene ontology (GO) term enrichment for biological processes are 
highlighted in Figure 3D. GO annotation of the 688 unique DE genes in EtOH (VEH) 
revealed a significant enrichment in genes associated with regulation of B cell 
differentiation, transocytosis and regulation of T cell mediated immunity among others. 
Genes overrepresented in these categories are shown in the clustergram in Figure 3D, 
where enriched terms are the columns, input genes are the rows, and the cell colors in 
the matrix indicate if a gene is associated with a term (red) based on its combined z-
score and p-value. The top 20 overrepresented genes included Zfp36, Zfp63LI, Cd27, 
BTK, Ikzf3, Inhba, Chrm5, Chrm2, Pfkfb1, Hdac4, Mfsd2a, Cltc, Picalm, Rab11b, 
Tfap2a, Erbb3, Tjp1, F11r, Was, Trpm4.  
Hdac4 was present in all top GO categories. Comparison of the total normalized gene 
expression of Hdac4 between treatment types is presented in Figure 3E. We observed 
a significant difference in expression between fluid types receiving vehicle treatment 
(two-way ANOVA: Fluid x Treatment interaction - F(1,41)=4.45, p< 0.05; main effect of 
fluid - F(1,41)=6.23, p<0.05; post-hoc test revealed EtOH(VEH) vs H2O(VEH), p < 
0.05).  
To identify the impact of chronic binge-drinking on gene correlation networks, 
WGCNA was performed and a 
hybrid network was constructed 
containing all the same groups 
as outlined in DE. The analysis 
of 19,671 (out of 24,421) genes 
identified 13 distinct modules 
containing ~100-5000 genes per 
module. The cluster 
dendrogram is illustrated in 
Figure 4A. Modules are color 
coded arbitrarily for clustered 
genes expressed across all 
treatments and fluid groups. 
Gene dissimilarity based on 
topological overlap (height) is 
assigned to module color. A 
table containing genes with the 
highest degree of correlation 
(hubs) in each module is 
presented in Figure 4B. The 
Figure 3. Effects of DREADDs and Drinking on Gene Networks. (A) 
Gene dendrogram showing the co-expression modules defined by labeled 
colors. Gene dis-similarity is shown as height. (B) Table describing module 
characteristics, hub genes and their descriptors, and module membership of 
unique DEGs identified in Figure 3. (C) Eigengene dendogram showing the 
correlation of modules as labeled colors corresponding the (B). The dis-
similarity of modules is expressed as height. (D) Matrix with the Module-Trait 
Relationships and corresponding p-values between the detected modules on 
the y-axis and fluid type and treatment traits on the x-axis. Module-Trait 
relationships are colored based on their correlation: red is a strong negative 
correlation, while blue is a strong positive correlation. * p < 0.05, ** p <0.01. 
 
relative module size is tabulated as well as the hub gene description and the number of 
unique DE genes in each module. Similarity between modules was identified through 
the clustering of module eigengenes. In Figure 4C, the module eigengene (ME) for each 
module was calculated and clustered to illustrate intra-modular relationships. Module 
dissimilarity based on eigengene topological overlap is expressed on the y-axis. 
Increased height corresponds to lower similarity between modules, while decreased 
height corresponds to increased similarity.  
Module susceptibility to group placement was determined by correlating MEs 
with group placement. Figure 4D illustrates the degree to which a module is correlated 
with each group. The correlation value is indicated in each cell, with the associated p-
value directly below. Modules are color coordinated based on correlation from positive 
(blue) to negative (red). White indicates minimal to no correlation of a module to a 
group. Only the brown module was found to be significantly, positively correlated to the 
EtOH(VEH) condition (p <0.01). Conversely, three modules were found to be 
significantly correlated to the EtOH (CNO) and two to H2O(VEH). The grey60 module 
was observed to be negatively correlated in EtOH(CNO) (p <0.05). The grey module 
represents unassigned genes, and was found to be significantly correlated to both 
EtOH(CNO) (positive, p< 0.05) and H2O(VEH) (negative, p <0.01). The light cyan 
module was uniquely positively correlated to EtOH(CNO) (p <0.05), while the black 










Figure 5. Effects of chronic Gq DREADD stimulation and Drinking on Neuron Morphology. Morphometric 
parameters analyzed for the dendrites of medium spiny neurons. Morphometric parameters of dendrites of nucleus 
accumbens medium spiny neurons from adult C57BL/6J mice injected with either CNO or a vehicle, and exposed to 
either EtOH or H2O were analyzed via Neurolucida Explorer. (A)  Complexity, calculated via the equation (sum of 
terminal orders + number of terminals) * (total dendrite length/number of dendrites). (B) Average dendrite length (total 
length/dendrite quantity) in µm. (C) Number of nodes per neuron. (D) Number of ends per neuron. (E) Total dendrite 
length per neuron, in µm. (F) Sum of the terminal orders (the number of sister branches encountered when tracing a 
dendrite from the tip back to the cell body). (G) Number of dendrites per neuron. (H) Branch sum per neuron (the total 
number of segments between nodes, a measure of cell branching). Shown in each graph is the mean ± the standard 
error (for neuron number per group see table #). Multilevel analyses were followed with multiple comparison 
corrections using the Benjamini-Hochberg approach to adjust p-values to the false discovery rate (FDR) (see table #).  
** q-value <0.01 (after FDR correction), + = p-value <0.05 (before FDR correction). 
Table 1.  
 
Table 2.  
 
 
Behavioral plasticity can be observed on a morphological level. Therefore, we 
analyzed medium spiny neurons in the nucleus accumbens for a variety of 
morphometric parameters, in order to determine the effects of treatment (CNO or 
vehicle), fluid type (EtOH or H2O), or whether there was an interaction between the two 
treatments. We analyzed neuronal complexity, determined via the equation (sum of 
terminal orders + number of terminals) * (total dendritic length/number of dendrites) 
(Figure 5A), length per dendrite (Figure 5B), number of nodes (Figure 5C), number of 
ends (Figure 5D), total length per neuron (Figure 5E), the sum of terminal orders, which 
is defined as the number of sister branches encountered when tracing a dendrite from 
the tip back to the cell body (Figure 5F), the quantity of dendrites (Figure 5G), and the 
branch sum, defined as the total number of segments between nodes (Figure 5H). In 
most parameters, there was an increase following exposure to EtOH (statistics for the 
analyses can are listed in Table 1). This effect was significant following corrections for 
multiple comparisons in neuronal complexity, the sum of terminal orders, and the 
branch sum, approached significance following corrections for multiple comparisons in 
the length per dendrite and the number of ends, and was significant before corrections 
for multiple comparisons in the number of nodes (Table 1). There was no significant 
change in the total dendritic length or the number of dendrites. There was also no effect 
of the injection (CNO or Vehicle), nor was there an interaction between the injection and 
exposure conditions. However, it is worth noting that the effect of EtOH was no longer 
seen after CNO injection.  
 
 
Figure 6. Sholl analysis and area under the curve analyzed for the dendrites of medium spiny neurons. Sholl 
analysis and area under the curve (AUC) of dendrites of nucleus accumbens medium spiny neurons from HDID-1 
mice injected with either CNO or a vehicle, and exposed to either EtOH or H2O were analyzed with Neurolucida 
Explorer. Radii were 10 µm each. Intersections per radius of H2O Veh vs. EtOH Veh (A), H2O CNO vs. EtOH CNO 
(B), and AUC (C). Length per radius of H2O Veh vs. EtOH Veh (D), H2O CON vs. EtOH CNO (E), and AUC (F). 
Nodes per radius of H2O Veh vs. EtOH Veh (G), H2O CNO vs. EtOH CNO (H) and AUC (I). Ends per radius of H2O 
Veh vs. EtOH Veh (J), H2O CNO vs. EtOH CNO (K) and AUC (L). Shown in each graph is the mean ± the standard 
error of the mean.  Multilevel analyses by radius (A, B, D, E, G, H, J, K) or for the total area (C, F, I, L) were followed 
with multiple comparisons corrections using the Benjamini-Hochberg approach to adjust p-values to the false 
discovery rate (FDR) (see table #1). * q-value <0.05 (after FDR correction), + = p-value <0.05 (before FDR 
correction). 
 
We also performed sholl analyses for these same neurons. We analyzed 
intersections (Figure 6A,B), length (Figure 6D,E), nodes (Figure 6G,H) and ends (Figure 
6J,K) by radius (10 µm), and examined each radius individually with multilevel analyses 
and corrections for multiple comparisons. As the primary effect seen in the neuron 
summary was an effect of EtOH in the vehicle injection condition, this is the comparison 
that we focused on. There were only sporadic significant differences in radii, with no 
overall pattern of effects in any variable (statistics for the analyses are listed in Table 2). 
Therefore, we elected to also examine the area under the curve (AUC). In this analysis, 
we found a similar effect as we did with the morphometric parameter analysis, as there 
was a greater AUC in the EtOH exposed groups when compared with H2O exposed 
groups, an effect which was significant in the nodes (Figure 6I) and ends (Figure 6L), 
and approached significance in intersections (Figure 6C) and length (Figure 6F). Also 
similar to the morphometric parameter analysis was that this difference between EtOH 
and H2O exposure was no longer seen in the CNO injection condition, although there 
was no interaction between the injection and exposure, or effect of the injection.  
 
Experiment 3: Pharmacologically testing the role of the overrepresented gene, 
Hdac4, in binge-like drinking  
The effects of HDAC4/5 inhibitor, LMK-235, on binge-like alcohol drinking were modest, 
but significant. Interestingly, they developed over several days and treatments 
(suggesting transcriptional mechanisms). When comparing ethanol intake across 
baseline and treatment weeks, a two way ANOVA revealed a significant main effect of 
treatment period on ethanol intake (Figure 7A; F(2,152)=5.16, p<0.01). Previous work 
has shown that the HDAC4/5 inhibitor, LMK-235, requires several administrations to 
exert its effects on signaling and morphology. We followed up on this finding by 
calculating a change score for each animal (by subtracting the average intake during 
treatment week 1 or week 2 from the average intake during baseline; shown in Figure 
7B). Two way ANOVA (dose x treatment week) revealed a significant main effect of 
dose and a significant main effect of treatment week [dose: F(2,76)=3.60, p<0.05; 
treatment week: F(1,76)=2.44, p<0.05]. 
 
 
Figure 7. Treatment with HDAC4/5 inhibitor, LMK-235, reduced binge-like alcohol drinking. (A) Average weekly 
ethanol intake after treatment with 0, 5 or 20 mg/kg LMK-235. Two way ANOVA revealed a significant main effect of 
treatment period on ethanol intake (Figure 7A; F(2,152)=5.16, p<0.01). (B) Ethanol intake presented as average 
difference score from baseline intake for each treatment week. Here significant reductions were observed for both 
doses over a two-week period [Two way ANOVA (dose x treatment week) revealed a significant main effect of dose 
and a significant main effect of treatment week [dose: F(2,76)=3.60, p<0.05; treatment week: F(1,76)=2.44, p<0.05]. 
DISCUSSION 
Despite its prevalence, those suffering from AUD often receive limited or no 
treatment. Currently, 3 FDA-approved medications are available for treatment: 
disulfiram, acamprosate and naltrexone (51). However, these medications are often 
underutilized, only work in a fraction of treated individuals to improve health outcomes, 
and improvements do not last beyond treatment (52). Further, although DBS of the NAc 
appears to be a potentially promising therapeutic approach, it is quite invasive and does 
not produce lasting reductions in drinking or craving. Thus, it is clear there exists a need 
for therapeutic approaches which produce robust and lasting effects. Here, we have 
shown that chronic binge-drinking induces lasting changes in gene expression networks 
and neuronal morphology, which can be ameliorated via chronic stimulation of Gq 
signaling (via CNO/hM3Dq) in the NAc. Further, we found that we could 
pharmacologically target HDAC4, a gene that is altered with chronic binge-like drinking 
and ameliorated with CNO/hM3Dq, to reduce binge drinking.    
 
Animal Models of Binge Drinking and DREADDs 
We and others have previously used HDID-1 mice as a reliable and predictive 
genetic model for high intensity binge-like drinking. This is due to their ability to achieve 
pharmacologically relevant blood alcohol levels (BALs), exhibit behavioral impairment 
after binge-like drinking and exhibit relapse and withdrawal behavior following binge 
sessions (6). Critically, it has been shown that genetic selection has not altered the 
preference of mice to other tastants, as well as their ability to metabolize alcohol (53). 
The DID paradigm was employed for its high-throughput, limited access approach which 
does not require the use of tastants to motivate high levels of ethanol consumption 
during the dark cycle when ingestive behavior is high. In our study, we observed robust 
reductions in ethanol intake of female HDID-1 mice expressing hM3Dq in the NAc when 
treated with CNO during a DID limited access paradigm. These effects were observed 
for the entirety of the CNO treatment period (28 days), suggesting mice expressing 
hM3Dq in the NAc did not develop tolerance or show sensitization in response to 
chronic treatment with CNO. Moreover, the decreased intake persisted for at least 7 
days during the vehicle “washout” period. We did not observe any change in ethanol 
drinking for mice expressing GFP or hM4Di in the NAc, suggesting our findings are 
specific to mice expressing hM3Dq. Purohit et al. (2018) showed that when CNO was 
administered acutely (2 days) or chronically (7 days) to C57BL/6J females, only mice 
expressing hM3Dq in the NAc showed reductions in binge-like drinking (36). This 
underscores that our findings are generalizable to more than one strain of mice. 
However, there may exist sex differences, or paradigm specific effects, in the effects of 
CNO/DREADDs for the NAc. Cassataro et al. (2014) found that CNO reduced binge-like 
drinking in C57BL/6J males (23). However, direct comparison of these studies should 
be cautioned since CNO was administered IP in the current study, as well as in Purohit 
et al. (2018), and via tap water in Cassataro et al. (2014) (23, 36). We are currently 
following up on these differences by conducting studies with both males and females to 
evaluate the role of sex as a biological factor. Similar studies that have been previously 
conducted in female C57BL/6J mice have shown that CNO injections do not impact 
water intake when comparing between mice expressing GFP, hM4Di, or hM3Dq in the 
NAc (36). Taken together, these results build strong evidence to suggest that chronic 
stimulation of the NAc in HDID-1 female mice produced behavioral plasticity resulting in 
lasting reductions of binge-like drinking. 
 
Effects of Chronic Binge-Drinking and DREADDs on the NAc Transcriptome  
Reductions in ethanol consumption observed during the washout period of the 
DID paradigm suggest lasting, plastic changes resulting due to chronic neuronal 
stimulation in mice expressing hM3Dq. Transcriptomic analyses were used to identify 
genes associated with binge-like drinking of ethanol which were ameliorated by CNO. 
Using Differential Expression analysis (DE), genes with significantly altered levels of 
expression were identified and contextualized within biological networks using Gene 
ontology analysis (GO). Weighted gene covariance network analysis (WGCNA) was 
used to construct a scale free network and identify modules. Genes with a high degree 
of network connectivity (hubs) that correlated with binge-like drinking were used to 
identify candidate biomarkers and therapeutic targets. Gene overlap identified from DE 
implicated changes in gene expression that were either treatment or/and fluid type 
specific. The 688 genes changed solely in the group EtOH (VEH) indicate genes whose 
expression was perturbed exclusively by chronic binge-like alcohol drinking. This is the 
first time that NAc transcriptomic changes related exclusively to either chronic binge-
drinking or chronic CNO stimulation of hM3Dq have been identified. For EtOH (CNO), 
1,431 genes were found to be related exclusively to those genes ameliorated by CNO 
treatment. Further, 612 genes were identified in the H2O (CNO) group and represented 
genes that were related exclusively to CNO treatment alone.  
 
Progression from acute to chronic alcohol intake, incites changes in gene 
expression levels that occur to maintain homeostasis under the increasing burden 
placed on the system by alcohol (54). Chronic exposure to alcohol causes dysregulation 
of these homeostatic mechanisms leading to alcohol abuse and dependence. In our 
work, we observed that of the 688 genes uniquely differentially expressed in the EtOH 
(VEH) group, those exhibiting the most extreme changes in expression, exhibited 
relatively reversed expression changes relative to the EtOH (CNO) and H2O (CNO) 
groups. We took this approach to identify genes which were explicitly changed by 
chronic binge drinking and ameliorated by CNO. Previous groups have observed similar 
outcomes in ethanol self-administration. In 2011, Mulligan et al, observed significant 
changes in gene expression in brain regions such as the striatum. 
They identified candidate genes and pathways altered by initial alcohol self-
administration by measuring global brain gene expression (using microarrays) in 
alcohol-preferring male C57BL/6J mice after a single bout of binge-like drinking (DID). 
Using DE analysis, they found that acute alcohol intake resulted in small, but consistent, 
changes in gene expression. Here, we found similar results; consistent changes in gene 
expression that were visualized in heat maps between groups were present across all 
groups relative to their treatment. Further, we observed many of the same unique 
differentially and co-expressed genes in both the EtOH (VEH) and EtOH (CNO) groups 
as those observed within the striatum by Mulligan et al; further supporting and validating 
the current findings. 
GO analysis of DE genes identified for the EtOH (VEH) group identified the 
importance of Hdac4 expression in binge drinking. In pathways such as regulation of B-
cell differentiation, transcytosis and regulation of T cell mediated immunity Hdac4 was 
consistently found to be overrepresented. Additionally, we observed gene 
representation related to circadian and neuroimmune pathways such as others have 
previously reported (55–57). Because Hdac4 was present in the majority of significant 
GO pathways, we took this to mean that Hdac4 played a large role in a number of 
biological pathways related to chronic binge drinking. 
We created a consensus network using WGCNA and identified that clustered 
modules were correlated to treatment and fluid groups. Here, treatment groups were 
treated as traits. EtOH (VEH) was considered to be the binge drinking trait without 
treatment, EtOH (CNO) binge drinking with treatment and H2O (CNO) treatment with 
CNO alone. Modules (containing groups of genes) significantly correlated to treatments 
were identified as being driven by a particular trait. In this way, most of the genes in a 
given module significantly correlated to a certain trait, would also exhibit a correlation 
with the trait of the same sign as the eigengene. The eigengene-trait correlation 
measured the strength and direction of association between the module (the 
representative profile) and the trait. Thus, if this was positive (or negative), it implied that 
the trait increased (or decreased) with increasing eigengene "expression". For example, 
the brown module was significantly correlated to the EtOH (VEH) trait [but not the EtOH 
(CNO) or H2O (CNO) traits], thus binge drinking was being driven positively by the 
majority of genes in the brown module. Interestingly, there were no modules 
significantly correlated with CNO. This implied that CNO had no significant impact on 
correlated gene changes and thus may have little to no significant effect on biological 
processes. This result is further supported previously by groups such as Jendryka et al., 
(2019) which showed that the conversion of CNO off targets are minimal at 1-5 mg/kg 
dosing (58). Thus, we infer that CNO alone present little to no significant impact on 
gene correlations. Further, we used our data set to query the LINCS L1000 database 
(59) and found low connectivity with clozapine, suggesting there no significant 
contribution from back metabolism of CNO to clozapine. 
Hdac4 was identified in the black module. This module was found to be 
significantly positively correlated to the H2O (VEH) trait, while being negatively 
correlated to the EtOH (VEH) trait. By nature, trait and module correlation is directly 
related to gene expression. Thus, this inverse correlation suggests that changes in gene 
expression are directly related to a difference in trait correlation. This implies that if 
Hdac4 expression were changed, it (as a regulatory gene) would induce a cascade of 
expression changes (in this particular differentially correlated module) that could 
ameliorate changes induced by binge drinking. The black module Hub is the gene 
Usp9x (Ubiquitin Specific Peptidase 9 X-linked or Deubiquitinase). Deubiquitinase is 
involved both in the processing of ubiquitin precursors and of ubiquitinated proteins. 
Thus, it may, play an important regulatory role at the level of protein turnover by 
preventing degradation of proteins through the removal of conjugated ubiquitin (60). 
Interestingly, GO analysis for transcription factors in this module revealed Hdac4 and 
Usp9x among other genes were highly over represented for the transcription factors 
Ctnnb1 and Jun. Both transcription factors regulate many genes with numerous, 
complex roles in cellular processes. Interestingly, although Hdac4 is not the primary hub 
gene within the black module, it is modulated by the same transcription factors as the 
hub gene and participates in a similar biological pathway. Thus, we infer that changing 
the expression of either of these genes would impact the overall correlation of the 
module they are found in to a particular trait. This result presents a significant finding for 
further pharmacological targeting of genes that participate in this module in order to 
ameliorate gene expression changes that are caused by binge-drinking. Taken together, 
these transcriptomic findings have resulted in the identification of Hdac4 and other 
genes, such as Usp9x, in this black module as important for amelioration of gene 
expression related to alcohol use disorders.  
 
Effects of Binge-Drinking and DREADDs on NAc Neuronal Morphology  
We found that chronic binge-like drinking resulted in increased complexity of 
medium spiny neurons in the NAc, an effect that was ameliorated by chronic treatment 
with CNO. Interestingly and unexpectedly, no effect of CNO was observed in water 
drinking mice, suggesting that chronically increasing Gq signaling in the NAc does not 
produce robust and lasting changes in neuronal complexity. We were unable to identify 
any published reports on the effects of DID or binge-like drinking on neuronal 
morphology in the NAc (or any other brain region) for comparison. However, there are 
several published studies evaluating the effects of chronic intermittent ethanol vapor on 
neuronal morphology in different brain regions. Most relevant to this work are studies by 
Wang et al. (2015), Uys et al. (2016), and DePoy et al. (2013) evaluating the effects of 
CIE on aspects of neuronal morphology in the dorsal and ventral striatum (61–63). In 
brief, these studies report that CIE results in increased spine density, increased 
dendritic diameter, increased dendritic length and number of processes. Although 
binge-like drinking in DID is likely modeling different aspects of AUD than CIE, it 
appears that both alcohol models result in morphological changes in the striatum that 
manifest as increased neuronal complexity, or dendritic hypertrophy.  
 
Pharmacologically Targeting HDAC4 to Reduce Binge-Like Drinking 
It has been shown that alcohol and withdrawal result in a global reduction of 
expressed transcripts, accompanied by an increase in expressed transcripts coding for 
regulators of epigenetic silencing (64). One such class of enzymes, histone 
deacetylases (HDAC; transcriptionally silencing enzymes), are inhibited by valproate. 
Valproate treatment during alcohol withdrawal reduces anxiety in dependent animals 
(65). Simon-O’Brien et al. (2012) reported that several classes of HDAC inhibitors and 
DNA methyltransferase inhibitors decrease alcohol-seeking behaviors (66). Thus, there 
is growing evidence that epigenetic modifiers and changes in gene expression play a 
role in alcohol behaviors. Here, we showed that the HDAC4/5 inhibitor LMK 235 
reduced binge-like drinking in mice selectively bred to drink to intoxication. Based on 
these results, we inferred that there were changes in transcriptional mechanisms 
because we observed that reductions in intake developed over several days and 
treatments. Although Hdac4 was selected as a target based on transcriptomic data from 
female mice, the compound reduced ethanol drinking in both male and female mice. 
Others have shown that HDAC4 is regulated by neuronal activity and plasticity, and 




Summary and Future Directions 
We chronically stimulated the nucleus accumbens in mice via CNO/DREADDs, 
which resulted in lasting reductions in high-intensity, binge-like alcohol drinking in mice. 
We were able to identify and target specific molecular pathways altered by alcohol but 
rescued by excitatory DREADDs using pharmacology (HDAC4/5 inhibitor) to mimic the 
behavioral effects of DREADDs and reduce binge drinking. Ongoing work is focused on 
using this data to identify and test compounds with high clinical translational potential. 
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